Many biotechnology companies in Germany are world leaders in their fields. The country's policy of consistent and early promotion of healthcare has in part fostered this level of excellence. A consistently dynamic, vibrant and competitive industrial climate has left German technology suppliers with decades of valuable, proven experience in realizing healthcare projects both at home and abroad.
Germany is home to nearly 580 dedicated biotechnology companies. Together they bring in more than EUR 3 billion in annual revenue. A third of these earnings they spend on R&D. These providers of products and services know how to develop and deliver customized solutions. Top that off with characteristics such as high levels of innovation, steady growth and continually developing employment potential to see why the German healthcare industry has a reputation for being a powerhouse in the field.
German companies do not innovate in splendid isolation. Germany's federal government funds the work of non-university research institutes, universities, and companies, which often collaborate on a range of projects. Oftentimes, the groundbreaking work is done at clusters of excellence, which also receive government and private financing. In 2016, the country's federal ministries spent EUR 4.5 billion on healthcare research. Special programs are often initiated to support important healthcare trends. An example of one is the EUR 360 million EU-wide program "Personalized Medicine 2020 and Beyond."
"Biotech companies from all over the globe have been using various approaches to enter their target market or to search for international partners. Even if they've thought early on about with whom they will collaborate or where to localize, most of the time they don't get sufficient information," says Axel Lohse, Manager for Medical Biotechnology and Pharmaceuticals at HEALTH MADE IN GERMANY, the German government's export initiative for the country's healthcare industry. Lohse continues, "Most of them already know that, besides the US and Japan, Germany offers one of the world's most competitive biotech markets. What is more, it is composed of many innovative companies centrally located right at the heart of Europe."
HEALTH MADE IN GERMANY bundles key information and contact details related to German healthcare companies and their products and services. "Our directories of German companies and research facilities provide direct contact details to help international businesses identify their German partner. We provide information about German in vitro diagnostics, bio-IT and digital health, CROs, CMOs etc. And we do it free of charge," says Lohse.
In September the group published the In Vitro Diagnostics Directory, the first such guide to include the primarily medium-sized companies active in this field. In addition to an overview of the IVD sector and market in Germany, the directory offers an analysis of the country's molecular diagnostics sector, an area where German companies have risen to global prominence.
Together with Germany Trade & Invest (GTAI), the foreign trade and inward investment agency of the Federal Republic of Germany, HEALTH MADE IN GERMANY publishes market briefs and in-depth market studies of the German healthcare industry and its different sectors.
Germany spends around EUR 344 billion, or 11.3 percent of its GDP, on healthcare annually. Those figures make Germany Europe´s biggest healthcare market. Furthermore, the country is one of the world's most important providers and exporters of healthcare products and services. Germany's innovative medical products set international standards for quality, safety and reliability. German manufacturers and service providers in all health and life sciences segments attract overseas customers and partners and deliver leadership in healthcare innovation.
An industry expert and Senior Manager of Investor Consulting for Chemicals & Healthcare at Germany Trade & Invest, Dr. Sandra Bütow adds, "Unfortunately, foreign enterprises planning to establish their business operations in Germany still often lack information on the business environment, such as the corporate investment framework, tax regulations, and subsidies. But they can obtain that information from me and the other industry experts at GTAI. We provide comprehensive project management and support services from site selection to the final realization of the investment. And of course, all inquiries are kept confidential and our investment services are free of charge."
One example is that colleagues from Saxony helped to launch a joint project between IZI and the Estonian company Selfdiagnostics with the aim of developing a quick home test to detect sexually transmitted bacterial pathogens."Such success stories are also our daily business and we also would be happy to help you," says Dr. Bütow.
"Both Germany Trade & Invest and HEALTH MADE IN GERMANY provide proactive support to get your business in touch with partners from Germany or to localize your business operations in Europe's biggest biotech and pharmaceuticals market," concludes Lohse.